Clinical Trials
3
Active:0
Completed:1
Trial Phases
3 Phases
Phase 2:1
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (33.3%)Phase 2
1 (33.3%)Phase 3
1 (33.3%)Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Phase 3
Recruiting
- Conditions
- Rectal Neoplasms
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 48
- Registration Number
- NCT06017583
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Phase 2
Recruiting
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 30
- Registration Number
- NCT05588219
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 120
- Registration Number
- NCT03086681
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
News
No news found